Skip to content

Study · Animal study (in vivo) · mouse · 2025

6 results

Acute mitochondrial reactive oxygen species emissions drive mitochondrial dysfunction after traumatic muscle injury in male mice.

Heo J, Miller DL, Hoffman JR, Oberholtzer E, Castelli KM, Sparagna GC, Fisher-Wellman KH, Greising SM, Call JA

American journal of physiology. Cell physiology4 Jun 2025Cited by 4 (Europe PMC)

PMID40465482 (opens in a new tab)PMCIDPMC12265971 (opens in a new tab)DOI10.1152/ajpcell.00407.2025 (opens in a new tab)PepBankPUB-40465482
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male mice with volumetric muscle loss, SS‑31 attenuated ROS emissions at 7 and 14 days postinjury.

    In plain wordsIn mice with muscle injury, SS‑31 lowered reactive oxygen species release from muscle mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS emissions at 7 and 14 dpi
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 attenuated ROS emissions at both 7 and 14dpi
    2 context sentences
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male mice with volumetric muscle loss, SS‑31 led to greater mitochondrial respiratory conductance and efficiency out to 30 dpi.

    In plain wordsIn mice with muscle injury, SS‑31 improved how well muscle mitochondria worked for up to 30 days.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial respiratory conductance and efficiency
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    led to greater mitochondrial respiratory conductance and efficiency out to 30 dpi.
    2 context sentences
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with volumetric muscle loss, SS‑31 boosted antioxidant buffering in injured muscle.

    In plain wordsIn mice with muscle injury, SS‑31 raised the muscle's antioxidant buffering.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseAntioxidant buffering capacity
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    A mitochondrial-targeted peptide, SS-31, improved mitochondrial efficiency, lowered ROS, and boosted antioxidant buffering in VML-injured muscle.
    2 context sentences
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with volumetric muscle loss, adding SS‑31 to wheel running did not produce greater contractile adaptations than rehabilitation alone.

    In plain wordsIn mice with muscle injury, adding SS‑31 to exercise did not improve muscle strength more than exercise alone.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeContractile adaptations with SS-31 plus wheel running
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Comparator
    Rehabilitation (wheel running) alone
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    Regenerative rehabilitation did not produce greater contractile adaptations, but there was modest evidence of greater metabolic adaptations compared with rehabilitation alone.
    3 context sentences
    Summary · context
    SS-31 and wheel running were combined in a regenerative rehabilitation model to determine whether attenuating acute ROS emissions improved adaptive capability of the remaining muscle.
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with volumetric muscle loss, adding SS‑31 to wheel running showed modest evidence of greater metabolic adaptations than rehabilitation alone.

    In plain wordsIn mice with muscle injury, adding SS‑31 to exercise gave slightly better metabolic adaptation than exercise alone.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMetabolic adaptations with SS-31 plus wheel running
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Comparator
    Rehabilitation (wheel running) alone
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    but there was modest evidence of greater metabolic adaptations compared with rehabilitation alone.
    3 context sentences
    Summary · context
    SS-31 and wheel running were combined in a regenerative rehabilitation model to determine whether attenuating acute ROS emissions improved adaptive capability of the remaining muscle.
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with volumetric muscle loss, lipidomic and proteomic analyses suggest SS‑31 altered redox protein abundance.

    In plain wordsIn mice with muscle injury, SS‑31 changed the amounts of proteins that handle oxidative stress.

    Peptide
    Elamipretide (SS-31)
    Outcome
    MixedRedox protein abundance
    Study

    mousen: not reported in source

    volumetric muscle loss injury
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    8 mg/kg/day · subcutaneous · up to 14 dpiAs given in this study (mouse).

    Source sentences

    Summary
    Lipidomic and proteomic analyses suggest that SS-31 contributes to redox protein abundance alterations after VML injury.
    2 context sentences
    Summary · context
    Male C57BL/6J mice were randomized into experimental and control groups.
    Summary · context
    SS-31, a mitochondrial-targeted peptide, was administered subcutaneously (8 mg/kg/day) for upto 14 dpi, and specific electron transport chain complex ROS emissions and mitochondrial bioenergetics were investigated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.